Skip to content
Screener

Corvus Pharmaceuticals CRVS Q3 2025 earnings

Reported November 4, 2025 · After market close

EPS-$0.12Beat by $0.02
EPS estimate-$0.14

Next report

Nov 3, 2026 (in a month)
EPS estimate-$0.21

Financials

Q3 2025

Income statement

See full
Operating income-$10.6M-45.7%
Net income-$10.2M+74.7%
EPS (diluted)-$0.12+80.0%

Balance sheet

See full
Cash & equivalents$2.9M-38.7%
Total debt$1.0M+186%
Total equity$71.8M+478%
Total assets$80.5M+36.8%

Cash flow

See full
Operating cash flow-$9.6M-51.3%
CapEx-—
Free cash flow-$9.6M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$549.17M+66.3%
Enterprise value$547.31M+67.9%

Returns & leverage

See full
Return on equity-35.8%-16.2pp
Debt / equity0×0.0×
Current ratio8.3×+7.4×

FAQ

When did Corvus Pharmaceuticals report Q3 2025 earnings?
Corvus Pharmaceuticals (CRVS) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Corvus Pharmaceuticals's Q3 2025 revenue and EPS?
Corvus Pharmaceuticals reported eps of $-0.12 for Q3 2025.
Did Corvus Pharmaceuticals beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.14 by $0.02.
How did Corvus Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 9.1% from $-0.11.
Where can I find Corvus Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001171843-25-006973) and the 10-Q periodic report (0001104659-25-106259) directly on SEC EDGAR. The filing index links above go to sec.gov.